

# MD7005/MD7255 - Advanced Injectable Therapies

Advanced Injectable Therapies

View Online



1.

Richard I. G. Holt, , Clive Cockram, , Allan Flyvbjerg, , and Barry J. Goldstein. Textbook of Diabetes. (John Wiley & Sons, Incorporated, 2016).

2.

Gururaj Setty, S., Crasto, W., Jarvis, J., Khunti, K. & Davies, M. J. New insulins and newer insulin regimens: a review of their role in improving glycaemic control in patients with diabetes. *Postgraduate Medical Journal* **92**, 152–164 (2016).

3.

Daly, H. et al. Development of a self-management education module for those with type 2 diabetes on injectable therapies. *Practical Diabetes* **32**, 305–310a (2015).

4.

Ajikumar B Aryangat & John E Gerich. Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk. *Vascular Health and Risk Management* **6**, (2010).

5.

Ashwell, S. G. et al. Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes. *Diabetic Medicine* **23**, 285–292 (2006).

6.

Bretzel, R. G. et al. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. *The Lancet* **371**, 1073–1084 (2008).

7.

Carver, C. Insulin Treatment and the Problem of Weight Gain in Type 2 Diabetes. *The Diabetes Educator* **32**, 910–917 (2006).

8.

Sharon Allard, Caroline Butler, Sue Cradock, Heather Daly, Jemma Edwards, Elizabeth Gilbert. Using Conversation Maps in practice: the UK experience. *Journal of Diabetes Nursing* **14**, (2010).

9.

Davies, M. J. et al. Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study. *Diabetes, Obesity and Metabolism* **11**, 1153–1162 (2009).

10.

Davies, M. J. et al. Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study. *Diabetes, Obesity and Metabolism* **11**, 1153–1162 (2009).

11.

Funnell, M. M. Overcoming Barriers to the Initiation of Insulin Therapy. *Clinical Diabetes* **25**, 36–38 (2007).

12.

Garber, A. J. et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). *Diabetes, Obesity and Metabolism* **8**, 58–66 (2006).

13.

Gough, S. C. L. A review of human and analogue insulin trials. *Diabetes Research and Clinical Practice* **77**, 1–15 (2007).

14.

Garber, A. J., Ligthelm, R., Christiansen, J. S. & Liebl, A. Premixed insulin treatment for type 2 diabetes: analogue or human? *Diabetes, Obesity and Metabolism* **9**, 630–639 (2007).

15.

Heller, S. R. et al. Hypoglycaemia with insulin aspart: a double-blind, randomised, crossover trial in subjects with Type 1 diabetes. *Diabetic Medicine* **21**, 769–775 (2004).

16.

Hermansen, K. et al. A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naive People With Type 2 Diabetes. *Diabetes Care* **29**, 1269–1274 (2006).

17.

Holman, R. R. et al. Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes. *New England Journal of Medicine* **357**, 1716–1730 (2007).

18.

Holman, R. R. & Turner, R. C. A Practical Guide to Basal and Prandial Insulin Therapy. *Diabetic Medicine* **2**, 45–53 (1985).

19.

Horvath, K. et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. in *Cochrane Database of Systematic Reviews* (John Wiley & Sons, Ltd, 1996). doi:10.1002/14651858.CD005613.pub3.

20.

Mäkimattila, S., Nikkilä, K. & Yki-Järvinen, H. Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus. *Diabetologia* **42**, 406–412 (1999).

21.

Malmberg, K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. *BMJ* **314**, 1512–1512 (1997).

22.

Ismail-Beigi, F. Glycemic Management of Type 2 Diabetes Mellitus. *New England Journal of Medicine* **366**, 1319–1327 (2012).

23.

Nathan, D. M. et al. Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care* **29**, 1963–1972 (2006).

24.

Marre, M. et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). *Diabetic Medicine* **26**, 268–278 (2009).

25.

Hirsch, I. B. et al. Options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapy. *Diabetes, Obesity and Metabolism* **16**, 206–214 (2014).

26.

Srinivasan, B. T. & Davies, M. Glycaemic management of type 2 diabetes. *Medicine* **42**,

711-717 (2014).

27.

Young, L. A. & Buse, J. B. GLP-1 receptor agonists and basal insulin in type 2 diabetes. *The Lancet* **384**, 2180-2181 (2014).

28.

Bergenstal, R. M. et al. Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes. *New England Journal of Medicine* **363**, 311-320 (2010).

29.

Diamant, M. et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. *The Lancet* **375**, 2234-2243 (2010).

30.

Gururaj Setty, S., Crasto, W., Jarvis, J., Khunti, K. & Davies, M. J. New insulins and newer insulin regimens: a review of their role in improving glycaemic control in patients with diabetes. *Postgraduate Medical Journal* **92**, 152-164 (2016).

31.

Rosenstock, J. et al. Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X). *Diabetes Care* **36**, 2945-2951 (2013).

32.

Bolinder, J., Antuna, R., Geelhoed-Duijvestijn, P., Kröger, J. & Weitgasser, R. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. *The Lancet* **388**, 2254-2263 (2016).

33.

Khunti, K. et al. Hypoglycemia and Risk of Cardiovascular Disease and All-Cause Mortality in Insulin-Treated People With Type 1 and Type 2 Diabetes: A Cohort Study. *Diabetes Care* **38**, 316–322 (2015).

34.

Inzucchi, S. E. et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care* **38**, 140–149 (2015).

35.

Htike, Z. Z. et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. *Diabetes, Obesity and Metabolism* (2017) doi:10.1111/dom.12849.

36.

Evans, M., Schumm-Draeger, P. M., Vora, J. & King, A. B. A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations. *Diabetes, Obesity and Metabolism* **13**, 677–684 (2011).

37.

Nauck, M. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. *Diabetes, Obesity and Metabolism* **18**, 203–216 (2016).

38.

Srinivasan, B. T., Jarvis, J., Khunti, K. & Davies, M. J. Recent advances in the management of type 2 diabetes mellitus: a review. *Postgraduate Medical Journal* **84**, 524–531 (2008).

39.

Home, P. D. The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences. *Diabetes, Obesity and Metabolism* **14**, 780–788 (2012).

40.

June James. Safety and insulin: implementation of national guidance at a local level. *Journal of diabetes nursing*.

41.

Rorsman, P. & Renström, E. Insulin granule dynamics in pancreatic beta cells. *Diabetologia* **46**, 1029–1045 (2003).

42.

L. Luzi. Effect of loss of first-phase insulin secretion on hepatic glucose production and tissue glucose disposal in humans. *American Journal of Physiology - Endocrinology and Metabolism* **257**, E241–E246 (1989).

43.

Luc JC van Loon. Plasma insulin responses after ingestion of different amino acid or protein mixtures with carbohydrate. *The American Journal of Clinical Nutrition* **72**, 96–105 (2000).

44.

Menting, J. G. et al. How insulin engages its primary binding site on the insulin receptor. *Nature* **493**, 241–245 (2013).

45.

Wahren, J. & Kallas, A. Loss of Pulsatile Insulin Secretion: A Factor in the Pathogenesis of Type 2 Diabetes? *Diabetes* **61**, 2228–2229 (2012).

46.

Richter, B. & Neises, G. 'Human' insulin versus animal insulin in people with diabetes mellitus. in *Cochrane Database of Systematic Reviews* (John Wiley & Sons, Ltd, 1996). doi:10.1002/14651858.CD003816.pub2.

47.

Crasto, W. et al. Insulin U-500 in severe insulin resistance in type 2 diabetes mellitus. *Postgraduate Medical Journal* **85**, 219–222 (2009).

48.

Swinnen, S. G., Simon, A. C., Holleman, F., Hoekstra, J. B. & DeVries, J. H. Insulin detemir versus insulin glargine for type 2 diabetes mellitus. in *Cochrane Database of Systematic Reviews* (John Wiley & Sons, Ltd, 1996). doi:10.1002/14651858.CD006383.pub2.

49.

Yki-Järvinen, H. et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. *Diabetologia* **49**, 442–451 (2006).

50.

Riddle, M. C. et al. Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin. *Diabetes Care* **36**, 2489–2496 (2013).

51.

Gough, S. C. L. et al. Low-Volume Insulin Degludec 200 Units/mL Once Daily Improves Glycemic Control Similarly to Insulin Glargine With a Low Risk of Hypoglycemia in Insulin-Naïve Patients With Type 2 Diabetes. *Diabetes Care* **36**, 2536–2542 (2013).

52.

Hirsch, I. B. et al. Options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapy. *Diabetes, Obesity and Metabolism* **16**, 206–214 (2014).

53.

Zinman, B. et al. Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. *The Lancet* **377**, 924–931 (2011).



54.

Horvath, K. et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. in Cochrane Database of Systematic Reviews (John Wiley & Sons, Ltd, 1996). doi:10.1002/14651858.CD005613.pub3.

55.

Buse, J. B. et al. Use of Twice-Daily Exenatide in Basal Insulin-Treated Patients With Type 2 Diabetes. *Annals of Internal Medicine* **154**, (2011).

56.

Rosenstock, J. et al. Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes. *Diabetes Care* **37**, 1815–1823 (2014).

57.

Frandsen, C. S. S. & Madsbad, S. Efficacy and safety of dipeptidyl peptidase-4 inhibitors as an add-on to insulin treatment in patients with Type 2 diabetes: a review. *Diabetic Medicine* **31**, 1293–1300 (2014).

58.

Hirsch, I. B., Franek, E., Mersebach, H., Bardtrum, L. & Hermansen, K. Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOST T1). *Diabetic Medicine* **34**, 167–173 (2017).

59.

Rodbard, H. W. et al. Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naïve people with Type 2 diabetes: the DUAL IV trial. *Diabetic Medicine* **34**, 189–196 (2017).

60.

Rosenstock, J. et al. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. *Diabetologia* **51**, 408–416 (2008).

61.

Raskin, P. et al. Initiating Insulin Therapy in Type 2 Diabetes: A comparison of biphasic and basal insulin analogs. *Diabetes Care* **28**, 260–265 (2005).

62.

Davies, M., Storms, F., Shutler, S., Bianchi-Biscay, M. & Gomis, R. Improvement of Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes: Comparison of two treatment algorithms using insulin glargine. *Diabetes Care* **28**, 1282–1288 (2005).

63.

Pickup, J. C., Reznik, Y. & Sutton, A. J. Glycemic Control During Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Insulin Injections in Type 2 Diabetes: Individual Patient Data Meta-analysis and Meta-regression of Randomized Controlled Trials. *Diabetes Care* **40**, 715–722 (2017).

64.

Davies, M. J. et al. Impact of baseline HbA1c, diabetes duration and BMI on clinical outcomes in the LixiLan-O trial testing iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) versus insulin glargine and lixisenatide monocomponents. *Diabetes, Obesity and Metabolism* (2017) doi:10.1111/dom.12980.

65.

Raccach, D. et al. Review of basal-plus insulin regimen options for simpler insulin intensification in people with Type 2 diabetes mellitus. *Diabetic Medicine* (2017) doi:10.1111/dme.13390.

66.

Marso, S. P. et al. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. *New*

England Journal of Medicine (2017) doi:10.1056/NEJMoa1615692.

67.

Wang, W. et al. Effects of Insulin Plus Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in Treating Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis. *Diabetes Therapy* (2017) doi:10.1007/s13300-017-0282-3.

68.

Villani, M., de Courten, B. & Zoungas, S. Emergency treatment of hypoglycaemia: a guideline and evidence review. *Diabetic Medicine* **34**, 1205–1211 (2017).

69.

Leelarathna, L. et al. Comparison of different insulin pump makes under routine care conditions in adults with Type 1 diabetes. *Diabetic Medicine* **34**, 1372–1379 (2017).

70.

Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia. - PubMed - NCBI.  
<http://www.ncbi.nlm.nih.gov/pubmed/18715200>.

71.

New IDegLira data show rapid and predictable glycaemic improvements in people with type 2 diabetes.  
<http://www.multivu.com/players/English/72762519-novo-nordisk-IDegLira-treatment/>.

72.

Anderson, B., Funnell, M., & American Diabetes Association. *The art of empowerment: stories and strategies for diabetes educators*. (American Diabetes Association, 2005).

73.

MacKinnon, M. *Providing diabetes care in general practice: a practical guide to integrated*

care. (Class, 2002).

74.

Walker, R. A., Rodgers, J., & Diabetes UK. Diabetes: a practical guide to managing your health. (Dorling Kindersley, 2010).

75.

Professor Kamlesh Khunti - Coding, Classification and Diagnosis of Diabetes. (4AD).

76.

Raccah, D. et al. Review of basal-plus insulin regimen options for simpler insulin intensification in people with Type 2 diabetes mellitus. *Diabetic Medicine* **34**, 1193–1204 (2017).